• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文会议>World congress of the International Photodynamic Association >The utilization of a non-invasive fluorescence imaging system to follow clinical dermatological MAL-PDT
【24h】

The utilization of a non-invasive fluorescence imaging system to follow clinical dermatological MAL-PDT

机译：利用非侵入性荧光成像系统跟踪临床皮肤病学MAL-PDT

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

This study employed a commercially available, non-invasive, fluorescence imaging system (Dyaderm, Biocam, Germany), to measure protoporphyrin IX (PpIX) concentration at several different stages during clinical dermatological methyl aminolevulinate photodynamic therapy (MAL-PDT). We validated the system prior to use to ensure that the PpIX changes witnessed were accurate and not due to environmental or user induced artifacts. The system was then employed to acquire color (morphological) and fluorescent (physiological) images simultaneously during dermatological PDT. Clinical data was collected from a range of licensed dermatological conditions (actinic keratosis, Bowen's disease and superficial basal cell carcinoma) during initial and subsequent PDT treatment cycles. The initial clinical data indicated that each type of licensed lesion considered responded in a similar manner following the application of Metvix? (Galderma, U.K.) and the subsequent light irradiation (Aktilite?, Galderma, U.K.). Images acquired three hours after Metvix application showed a significant increase in PpIX concentration within the lesion (P < 0.05), whilst PpIX levels in the surrounding normal tissue remained unaltered. After irradiation, the PpIX concentration was significantly decreased and returned to a level similar to the initial concentration originally observed. Lesions that received subsequent treatment cycles accumulated significantly less PpIX (P < 0.05) prior to irradiation.
机译：这项研究采用了市售的无创荧光成像系统（Dyaderm，Biocam，德国），在临床皮肤病学氨基乙酰丙酸光动力疗法（MAL-PDT）的几个不同阶段测量原卟啉IX（PpIX）的浓度。我们在使用之前验证了系统，以确保所见证的PpIX更改是准确的，而不是由于环境或用户引起的伪影。然后使用该系统在皮肤科PDT期间同时获取彩色（形态）和荧光（生理）图像。在初始和随后的PDT治疗周期中，从一系列许可的皮肤病学条件（光化性角化病，Bowen病和浅表性基底细胞癌）中收集临床数据。最初的临床数据表明，应用Metvix®后，所考虑的每种许可病变均以相似的方式发生反应。 （英国，Galderma）和随后的光照射（英国，Galderma）。 Metvix应用后三小时获得的图像显示病变内PpIX浓度显着增加（P <0.05），而周围正常组织中PpIX的水平保持不变。辐照后，PpIX浓度显着降低，并恢复到与最初观察到的初始浓度相似的水平。接受后续治疗周期的病变在照射前积累的PpIX明显较少（P <0.05）。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号